PACB
$1.38
Pacific Biosciences of California, Inc.
Recent News
Fortrea, Alignment Healthcare, PacBio, DexCom, and Humana Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries.
3 of Wall Street’s Favorite Stocks We Think Twice About
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Why The PacBio (PACB) Investment Story Is Shifting As Analysts Cut Targets And Flag Risks
Pacific Biosciences of California is back in focus after analysts cut their price target to $1.50 from $2, while a separate fair value estimate was trimmed to $2.43 from $2.50. This shift is tied to an Underweight rating, along with fresh worries about near term demand for sequencing consumables, growth visibility, and a possible pause in orders ahead of new competitive launches. Read on to see what these changes might mean for you and how to track the evolving story around the stock. Analyst...
PacBio, CONMED, Moderna, QuidelOrtho, and Tandem Diabetes Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses.
Life Sciences Tools & Services Stocks Q4 Recap: Benchmarking PacBio (NASDAQ:PACB)
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at PacBio (NASDAQ:PACB) and its peers.